{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:51:32Z","timestamp":1790146292445,"version":"4.0.1"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100005737","name":"Universit\u00e9; Pierre et Marie Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004562","name":"Minist\u00e8re de l'Education Nationale, de l'Enseignement Superieur et de la Recherche","doi-asserted-by":"publisher","award":["UPRES EA 1541"],"award-info":[{"award-number":["UPRES EA 1541"]}],"id":[{"id":"10.13039\/501100004562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The second-line injectable drugs (SLID, i.e., amikacin, kanamycin, capreomycin) are key drugs for the treatment of multidrug-resistant tuberculosis. Mutations in\n            <jats:italic>rrs<\/jats:italic>\n            region 1400,\n            <jats:italic>tlyA<\/jats:italic>\n            , and\n            <jats:italic>eis<\/jats:italic>\n            promoter are associated with resistance to SLID, to capreomycin, and to kanamycin, respectively. In this study, the sequencing data of SLID resistance-associated genes were compared to the results of phenotypic drug susceptibility testing by the proportion method for the SLID in 206 multidrug-resistant clinical isolates of\n            <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n            collected in France. Among the 153 isolates susceptible to the 3 SLID, 145 showed no mutation, 1 harbored T1404C and G1473A mutations in\n            <jats:italic>rrs<\/jats:italic>\n            , and 7 had an\n            <jats:italic>eis<\/jats:italic>\n            promoter mutation. Among the 53 strains resistant to at least 1 of the SLID, mutations in\n            <jats:italic>rrs<\/jats:italic>\n            accounted for resistance to amikacin, capreomycin, and kanamycin for 81%, 75%, and 44% of the isolates, respectively, while mutations in\n            <jats:italic>eis<\/jats:italic>\n            promoter were detected in 44% of the isolates resistant to kanamycin. In contrast, no mutations in\n            <jats:italic>tlyA<\/jats:italic>\n            were observed in the isolates resistant to capreomycin. The discrepancies observed between the genotypic (on the primary culture) and phenotypic drug susceptibility testing were explained by (i) resistance to SLID with MICs close to the critical concentration used for routine DST and not detected by phenotypic testing (\n            <jats:italic>n<\/jats:italic>\n            = 8, 15% of SLID-resistant strains), (ii) low-frequency heteroresistance not detected by sequencing of drug resistance-associated genes on the primary culture (\n            <jats:italic>n<\/jats:italic>\n            = 8, 15% of SLID-resistant strains), and (iii) other resistance mechanisms not yet characterized (\n            <jats:italic>n<\/jats:italic>\n            = 7, 13% of SLID-resistant strains).\n          <\/jats:p>","DOI":"10.1128\/aac.01299-16","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T02:31:07Z","timestamp":1480386667000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of\n            <i>Mycobacterium tuberculosi<\/i>\n            s in France"],"prefix":"10.1128","volume":"61","author":[{"given":"Florence","family":"Brossier","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux, Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bernard","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux, Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux, Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jarlier","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux, Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux, Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimir","family":"Sougakoff","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Team E13 (Bacteriology), Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Centre National de R\u00e9f\u00e9rence des Mycobact\u00e9ries et de la R\u00e9sistance des Mycobact\u00e9ries aux Antituberculeux, Bact\u00e9riologie-Hygi\u00e8ne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CNR-MyRMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"WHO\/HTM\/TB\/2016.13","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. Global tuberculosis report 2016. WHO\/HTM\/TB\/2016.13. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"WHO HTM\/TB\/2011.6","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO HTM\/TB\/2011.6. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155708"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01947-09"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055292"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00197-11"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033275"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3192-3197.2005"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04438-14"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.06.031"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00050-09"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010705.pub2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1295"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-09"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2971-2973.2003"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01775-16"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907925106"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02059-14"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks178"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.05.044"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.571-577.2005"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr109"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01476-09"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-10"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2672.2010.04840.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp452"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2011.0063"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00472-13"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00857-13"},{"key":"e_1_3_3_31_2","volume-title":"The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. WHO\/HTM\/TB\/2016.07. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2878"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00553-13"},{"key":"e_1_3_3_34_2","volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO\/HTM\/TB\/2014.11. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00393-16"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02191-12"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00626-13"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2015.10.012"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00062-6"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00051-16"},{"key":"e_1_3_3_41_2","volume-title":"Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO\/HTM\/TB\/2008.392. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00240-10"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01392-06"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01299-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01299-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:42:17Z","timestamp":1645476137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01299-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1128\/AAC.01299-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01299-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"2016-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01299-16"}}